DAVIE, FL / ACCESSWIRE / November 15, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), is pleased to announce that...
Read moreSKYX Platforms Corp. today announced that it will host a virtual investor event on Thursday, November 17, 2022, at 11:00am...
Read moreNephron Pharmaceuticals Corporation and Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”), announced today a new partnership focused on developing and...
Read moreJupiter Wellness, Inc. (Nasdaq:JUPW), announced today that it has re-opened enrollment in a clinical trial aimed at evaluating the superiority...
Read moreMawson Infrastructure Group Inc. (NASDAQ:MIGI) announced today, that the company has scheduled a webcast for November 14, 2022 at 5:00...
Read moreLongeveron Inc. (NASDAQ: LGVN) announced today, the completion of enrollment in its Phase 2a trial of Lomecel-BTM in patients with...
Read moreSciSparc Ltd. (Nasdaq: SPRC), announced today that the U.S. Patent and Trademark Office has granted it a new patent -...
Read moreJupiter Wellness, Inc. (Nasdaq:JUPW), today announced that it has plans to transfer and spin-off forty percent (40%) of the Company's...
Read moreJupiter Wellness, Inc. (Nasdaq: JUPW), has been approved by the CDSCO for sale in India. The Central Drugs Standard Control...
Read moreMill City Ventures III, Ltd. announced today its funding of a settled insurance claim in the amount of $855,000. The...
Read moreThese Next Steps are EXTREMELY IMPORTANT because the only way to get our Featured Top Stock Alerts is to reply back to the message you just received by answering YES.
CLICK HERE TO REPLY BACK
YES ON YOUR CELL PHONE
To make sure you are in, please check your cell phone for a message from 16462224464 (make sure you save that number on your contacts under "StockTips") If you don't see the message check "Unknown Senders" on your phone.
If you did not receive the text message on your cell phone, then grab your phone right now and text the word "MOMO" to "16462224464"
© 2022 OpenEquity Research - Investment-Grade Research for the rest of us.
© 2022 OpenEquity Research - Investment-Grade Research for the rest of us.